Publications by authors named "Mark Kia Ik Tan"
Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave.
Nicola Sweeney Blair Merrick Rui Pedro Galão Suzanne Pickering Alina Botgros Gilberto Betancor Mark Kia Ik Tan
PLoS One
April 2021
During the first wave of the global COVID-19 pandemic the clinical utility and indications for SARS-CoV-2 serological testing were not clearly defined. The urgency to deploy serological assays required rapid evaluation of their performance characteristics. We undertook an internal validation of a CE marked lateral flow immunoassay (LFIA) (SureScreen Diagnostics) using serum from SARS-CoV-2 RNA positive individuals and pre-pandemic samples.
View Article and Find Full Text PDFArticle Synopsis
- Antibody responses to SARS-CoV-2 usually appear in most infected individuals within 10-15 days after symptoms start, but it's unclear how long they last or if they protect against reinfection.
- The study analyzed serum samples from 65 confirmed cases over 94 days and found that over 95% of individuals developed various antibody types, with neutralizing antibodies detected after 8 days post-symptom onset.
- Results indicated that while some individuals retained high neutralizing antibody levels for more than 60 days, others experienced a significant decline, suggesting that booster vaccinations may be necessary for sustained protection against COVID-19.